NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

Phase 3

Active, not recruiting

Conditions: Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
Endometrial Clear Cell Adenocarcinoma
Endometrial Dedifferentiated Carcinoma
Endometrial Endometrioid Adenocarcinoma
Endometrial Mixed Cell Adenocarcinoma
Endometrial Serous Adenocarcinoma
Endometrial Undifferentiated Carcinoma
Recurrent Endometrial Adenocarcinoma
Recurrent Endometrial Carcinoma
Recurrent Endometrial Clear Cell Adenocarcinoma

Interventions: Drug: Carboplatin
Procedure: Computed Tomography
Drug: Paclitaxel
Other: Placebo Administration
Biological: Pembrolizumab
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2019-04-16

Last Posted Date: 2025-06-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 813

Registration Number: NCT03914612

Locations: 🇺🇸
Saint Luke's Cancer Institute - Boise, Boise, Idaho, United States
🇺🇸
Saint Alphonsus Cancer Care Center-Caldwell, Caldwell, Idaho, United States
🇺🇸
Saint Luke's Cancer Institute - Fruitland, Fruitland, Idaho, United States

and more 393 locations

Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer

Phase 2

Active, not recruiting

Conditions: Differentiated Thyroid Gland Carcinoma
Follicular Variant Thyroid Gland Papillary Carcinoma
Poorly Differentiated Thyroid Gland Carcinoma
Refractory Thyroid Gland Carcinoma
Refractory Differentiated Thyroid Gland Carcinoma
Tall Cell Variant Thyroid Gland Papillary Carcinoma
Thyroid Gland Follicular Carcinoma
Thyroid Gland Oncocytic Carcinoma
Thyroid Gland Papillary Carcinoma

Interventions: Procedure: Biospecimen Collection
Drug: Cabozantinib S-malate
Procedure: Computed Tomography
Biological: Ipilimumab
Procedure: Magnetic Resonance Imaging
Biological: Nivolumab

First Posted Date: 2019-04-16

Last Posted Date: 2024-12-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 9

Registration Number: NCT03914300

Locations: 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
University of Kansas Cancer Center-Overland Park, Overland Park, Kansas, United States
🇺🇸
University of Utah Sugarhouse Health Center, Salt Lake City, Utah, United States

and more 30 locations

Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple Myeloma

Phase 2

Terminated

Conditions: Myeloma, Multiple
Myeloma-Multiple

Interventions: Biological: Avelumab
Radiation: External beam radiotherapy

First Posted Date: 2019-04-10

Last Posted Date: 2021-05-12

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 4

Registration Number: NCT03910439

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Children and Adults With Chordoma

Recruiting

Conditions: Chordoma

First Posted Date: 2019-04-10

Last Posted Date: 2025-06-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 300

Registration Number: NCT03910465

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

Phase 3

Active, not recruiting

Conditions: Lymphocyte-Rich Classic Hodgkin Lymphoma
Ann Arbor Stage III Hodgkin Lymphoma
Classic Hodgkin Lymphoma
Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma
Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma
Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma
Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma
Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma
Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma
Ann Arbor Stage IV Hodgkin Lymphoma

Interventions: Procedure: Biospecimen Collection
Drug: Brentuximab Vedotin
Procedure: Computed Tomography
Drug: Dacarbazine
Drug: Doxorubicin Hydrochloride
Biological: Filgrastim
Procedure: Magnetic Resonance Imaging
Biological: Nivolumab
Biological: Pegfilgrastim
Procedure: Positron Emission Tomography
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Radiation: Radiation Therapy
Drug: Vinblastine Sulfate

First Posted Date: 2019-04-09

Last Posted Date: 2025-01-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 994

Registration Number: NCT03907488

Locations: 🇺🇸
The Carle Foundation Hospital, Urbana, Illinois, United States
🇺🇸
Northwestern Medicine Cancer Center Warrenville, Warrenville, Illinois, United States
🇺🇸
Illinois CancerCare - Washington, Washington, Illinois, United States

and more 731 locations

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVA+ Study)

Phase 2

Recruiting

Conditions: Metastatic Malignant Solid Neoplasm
Locally Advanced Malignant Solid Neoplasm

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Capecitabine
Drug: Carboplatin
Biological: Durvalumab
Drug: Gemcitabine Hydrochloride
Procedure: Echocardiography Test
Drug: Paclitaxel
Drug: Nab-paclitaxel
Drug: Pegylated Liposomal Doxorubicin Hydrochloride

First Posted Date: 2019-04-09

Last Posted Date: 2025-04-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 115

Registration Number: NCT03907475

Locations: 🇺🇸
National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland, United States

Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies

Phase 1

Completed

Conditions: Peripheral T-cell Lymphoma NOS
Mycosis Fungoides
Sezary Syndrome
Anaplastic Large Cell Lymphoma

Interventions: Drug: rhIL-15
Biological: Avelumab

First Posted Date: 2019-04-05

Last Posted Date: 2022-09-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 8

Registration Number: NCT03905135

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs

Phase 2

Active, not recruiting

Conditions: Limited Stage Lung Small Cell Carcinoma
Platinum-Resistant Lung Small Cell Carcinoma
Platinum-Sensitive Lung Small Cell Carcinoma
Extensive Stage Lung Small Cell Carcinoma
Extrapulmonary Small Cell Neuroendocrine Carcinoma
Recurrent Lung Small Cell Carcinoma

Interventions: Procedure: Biopsy Procedure
Drug: Berzosertib
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Topotecan Hydrochloride

First Posted Date: 2019-04-01

Last Posted Date: 2025-04-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 104

Registration Number: NCT03896503

Locations: 🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
USC Norris Oncology/Hematology-Newport Beach, Newport Beach, California, United States

and more 30 locations

Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)

Phase 2

Recruiting

Conditions: Non-Alcoholic Steatohepatitis
Non-Alcoholic Fatty Liver Disease

Interventions: Drug: Semaglutide

First Posted Date: 2019-03-21

Last Posted Date: 2025-02-17

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 84

Registration Number: NCT03884075

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

A Phase II Clinical Trial Evaluating the Combination of Olaparib and Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma

Phase 2

Active, not recruiting

Conditions: Uterine Corpus Leiomyosarcoma
Stage III Uterine Corpus Leiomyosarcoma AJCC v8
Stage IV Uterine Corpus Leiomyosarcoma AJCC v8

Interventions: Procedure: Computed Tomography
Procedure: Core Biopsy
Procedure: Magnetic Resonance Imaging
Drug: Olaparib
Drug: Temozolomide

First Posted Date: 2019-03-19

Last Posted Date: 2025-04-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 23

Registration Number: NCT03880019

Locations: 🇺🇸
Weisberg Cancer Treatment Center, Farmington Hills, Michigan, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 12 locations

Home Terms & Conditions Privacy Policy